Last reviewed · How we verify
NCT04542642
A Remote, Decentralized Opioid Use Disorder Study to Evaluate Patient Engagement With a Game-Based Digital Therapeutic
NA trial testing reSET-O in Opioid-use Disorder in 52 participants. Completed in 23 November 2022.
16 November 2022
Quick facts
| Lead sponsor | Pear Therapeutics, Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 52 |
| Start date | 19 May 2021 |
| Primary completion | 16 November 2022 |
| Estimated completion | 23 November 2022 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- reSET-O
- PEAR-008
Conditions studied
- Opioid-use Disorder — all drugs for Opioid-use Disorder →
Sponsor
Pear Therapeutics, Inc.
Who can join
Adults 18 to 60, any sex, with Opioid-use Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate how patients use and engage with a game-based mobile application that is designed to treat opioid use disorder.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Patient Engagement With a Game-Based Digital Therapeutic for the Treatment of Opioid Use Disorder: Protocol for a Randomized Controlled Open-Label, Decentralized Trial.
Luderer H, Chiodo L, Wilson A, Brezing C, et al · · 2022 · cited 4× · PMID 35080499 · DOI 10.2196/32759
Verify or expand the search:
- PubMed search for NCT04542642
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of reSET-O
Trials testing the same drug.
- NCT05412966 — Feasibility Study of Novel Prescription Digital Therapeutic Supporting Unobserved Buprenorphine Initiation & Adherence · NA · completed
Other recruiting trials for Opioid-use Disorder
Currently open trials in the same condition.
- NCT04783558 — Effective Caregiving for Neonatal Abstinence Syndrome: Testing an Instructional Mobile Technology Platform for High-Risk · NA · active not recruiting
- NCT05011266 — Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder · Phase 2, PHASE3 · recruiting
- NCT05039554 — Randomized Trial of ACT and a Care Management App in Primary Care-based Buprenorphine Treatment · NA · recruiting
- NCT05033028 — Smartphones for Opiate Addiction Recovery · Phase 3 · recruiting
- NCT04738825 — Promoting HIV Risk Reduction Among People Who Inject Drugs: A Stepped Care Approach Using Contingency Management With Pr · NA · recruiting
Other Pear Therapeutics, Inc. trials
Trials by the same sponsor.
- NCT05412966 — Feasibility Study of Novel Prescription Digital Therapeutic Supporting Unobserved Buprenorphine Initiation & Adherence · NA · completed
- NCT04325464 — A Remote, 9-week Insomnia Treatment Trial to Collect Real World Data for a Digital Therapeutic · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04542642 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pear Therapeutics, Inc.
- Last refreshed: 14 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04542642.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing